IBRX

ImmunityBio (IBRX)

ImmunityBio Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:IBRX

1 2 3 4 5 6 7 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/06/14	07:50	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IBRX	ImmunityBio Inc
2024/06/14	07:49	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IBRX	ImmunityBio Inc
2024/06/14	07:49	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IBRX	ImmunityBio Inc
2024/06/14	07:49	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IBRX	ImmunityBio Inc
2024/06/14	07:49	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IBRX	ImmunityBio Inc
2024/06/14	07:49	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IBRX	ImmunityBio Inc
2024/06/13	05:36	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IBRX	ImmunityBio Inc
2024/06/07	22:13	Business Wire	ImmunityBio Announces 2024 Annual Meeting of Stockholders with Company Update	NASDAQ:IBRX	ImmunityBio Inc
2024/05/17	22:00	Business Wire	Connecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast	NASDAQ:IBRX	ImmunityBio Inc
2024/05/10	06:00	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:IBRX	ImmunityBio Inc
2024/05/07	21:00	Business Wire	ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®	NASDAQ:IBRX	ImmunityBio Inc
2024/05/03	05:04	Business Wire	ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types	NASDAQ:IBRX	ImmunityBio Inc
2024/04/30	21:00	Business Wire	ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association	NASDAQ:IBRX	ImmunityBio Inc
2024/04/25	13:03	Business Wire	ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer	NASDAQ:IBRX	ImmunityBio Inc
2024/04/23	10:56	Business Wire	ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer	NASDAQ:IBRX	ImmunityBio Inc
2024/03/06	23:00	Business Wire	NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy	NASDAQ:IBRX	ImmunityBio Inc
2024/03/05	23:00	Business Wire	N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study	NASDAQ:IBRX	ImmunityBio Inc
2024/02/27	06:43	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IBRX	ImmunityBio Inc
2024/02/27	06:40	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IBRX	ImmunityBio Inc
2024/02/27	06:38	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IBRX	ImmunityBio Inc
2024/02/24	11:28	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IBRX	ImmunityBio Inc
2024/02/21	23:00	Business Wire	ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial	NASDAQ:IBRX	ImmunityBio Inc
2024/02/07	11:14	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IBRX	ImmunityBio Inc
2024/02/05	23:00	Business Wire	ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG	NASDAQ:IBRX	ImmunityBio Inc
2024/02/03	09:38	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IBRX	ImmunityBio Inc
2024/02/03	09:33	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IBRX	ImmunityBio Inc
2024/01/04	11:59	Edgar (US Regulatory)	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]	NASDAQ:IBRX	ImmunityBio Inc
2024/01/04	11:41	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IBRX	ImmunityBio Inc
2024/01/04	11:40	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IBRX	ImmunityBio Inc
2024/01/02	20:08	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IBRX	ImmunityBio Inc